Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component

Phase 4TerminatedNCT01838044

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.180 enrolled

Overview

The purpose of this study is to determine if treatment with celecoxib and pregabalin together would prove to be more effective in relief of pain than treatment with celecoxib alone in people who have chronic low back pain with a probable neuropathic component.

The primary objective is to evaluate the efficacy of the concomitant use of pregabalin and celecoxib compared with celecoxib monotherapy for the symptomatic relief of pain in patients with chronic low back pain with a probable neuropathic component. The secondary objectives are: * Demonstrate the additional benefit of adding pregabalin to celecoxib monotherapy. * To evaluate the concomitant use of pregabalin and celecoxib compared to celecoxib monotherapy in a set of patient reported measures (sleep, depression, anxiety, impact of pain in daily functions, patient's global impression of change and patient's perception of the treatment). * To evaluate the safety and tolerability of celecoxib and of the concomitant administration of pregabalin and celecoxib.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

180

Conditions

Chronic Low Back Pain With a Neuropathic Component

Interventions

pregabalin and celecoxibDRUG

During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily. All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.

Placebo and celecoxibDRUG

Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily. All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must have Chronic low back pain with high probability of a significant neuropathic component for 4 years or less (but no less than 3 months) * Subjects must be in generally good health, except for the presence of chronic low back pain with a neuropathic component. * Subjects must be literate and have the ability (unaided) to understand and use the interactive voice response system (IVRS), have daily access to a telephone or the internet in order to complete the IVRS assessments each day, perform telephone or web visits and complete all required assessments/forms Exclusion Criteria: * Subjects with past history of surgery for chronic low back pain. * Subjects with past history of failure on pregabalin treatment and/or intolerance associated with pregabalin or gabapentin. * Subjects with past history of intolerance associated with celecoxib or known hypersensitivity to celecoxib. * Patients with anticipated need for treatment with opioid analgesics, anti-epileptic medications, SNRI antidepressants or tricyclic antidepressants to alleviate pain during the course of the study. * Patients with chronic low back pain with a neuropathic component for more than 4 years. * Patients with neurologic disorders unrelated to low back pain that may confuse or confound the assessment of neuropathic pain (eg, primary or secondary nerve diseases). * Subjects considered at risk of suicide or self-harm based on investigator judgment and/or details of a risk assessment. * Use of prohibited medications in the absence of appropriate washout periods. * Patients with any severe pain associated with conditions other than chronic low back pain with a neuropathic component that may confound the assessment or self-evaluation of the pain due to chronic low back pain. * Patients with diabetes with poor glycemic control (HbA1c \>8%). * Patients with any clinically significant or unstable medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, would compromise participation in the study * Patients who have participated in any previous clinical trial for pregabalin or have participated in 2 or more previous clinical trials for pain related to chronic low back pain. * Patients who are likely to require surgery during the course of the study (except minor surgery, eg, for skin conditions) * Patients with a history of Substance Abuse as defined by DSM-IV-TR diagnostic criteria

Locations (29)

Outcomes

Primary Outcomes

Change From Baseline in the Weekly Mean Pain Numeric Rating Scale (NRS) Score at Week 5 (ie, Visit 4) Compared Between the Two Study Arms

The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

Time frame: Baseline and Week 5

Secondary Outcomes

Change in the Weekly Mean Pain NRS Score in Arm B, Compared Between Week 5 (Visit 4) and Week 10 (Visit 6).

Time frame: Week 5 and Week 10

Change From Baseline in the Weekly Mean Pain NRS Score at Week 10 (Visit 6) Compared Between the Two Study Arms

Time frame: Baseline and Week 10

Change From Baseline in Benefit, Satisfaction, and Willingness to Continue Measure Scores Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)

The BSW consists of 3, single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was administered by the investigator or designated site personnel in the local language as a standardized interview during the follow-up visits. The BSW can potentially be self-administered; however, this method of administration has not been tested. Participants completed this questionnaire at Visit 4 and Visit 6.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Centro de Pesquisa Clínica do Hospital Universitário da Universidade Federal do Maranhão - CEPEC

São Luís, Maranhão, Brazil

Santa Casa de Misericórdia de Belo Horizonte

Belo Horizonte, Minas Gerais, Brazil

CMIP-Centro Mineiro de Pesquisa

Juiz de Fora, Minas Gerais, Brazil

EDUMED Educação em Saúde - Centro de Pesquisas Clínicas

Curitiba, Paraná, Brazil

Faculdade de Medicina do ABC

Santo André, São Paulo, Brazil

Instituto Paulista de Reumatologia da UNIFESP

São Paulo, São Paulo, Brazil

Instituto de Pesquisa Clinica e Medicina Avancada - IMA Brasil

São Paulo, Brazil

Centro de Diagnostico y Tratamiento Ltd. Clinica Siresa

Temuco, Región de la Araucanía, Chile

Centro de Investigación Clínica Neuropsicología Ltda

La Florida, Santiago Metropolitan, Chile

Fundacion Cardiovascular de Colombia - Instituto del Corazon Floridablanca

Floridablanca, Santander Department, Colombia

...and 19 more locations